B. Metzler seel. Sohn & Co’s Nurix Therapeutics NRIX Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-36,171	Closed	-$373K	–	768
2023 Q4	$373K	Buy	36,171 +9,133	+34%	+$62.6K	﹤0.01%	642
2023 Q3	$213K	Sell	27,038 -27,038	-50%	-$247K	﹤0.01%	700
2023 Q2	$540K	Buy	54,076 +36,739	+212%	+$375K	0.01%	576
2023 Q1	$154K	Buy	17,337 +4,526	+35%	+$47.2K	﹤0.01%	720
2022 Q4	$141K	Buy	12,811 +2,418	+23%	+$29.2K	﹤0.01%	713
2022 Q3	$135K	Buy	+10,393	New	+$164K	﹤0.01%	723

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

B. Metzler seel. Sohn & Co's NRIX Position: Q1 2024 in Review

B. Metzler seel. Sohn & Co sold out of Nurix Therapeutics (NRIX) in Q1 2024, closing a stake of 36,171 shares — an estimated $373K sold.

B. Metzler seel. Sohn & Co first reported a position in NRIX in Q3 2022 and held it in 6 quarters. The position peaked at $540K in Q2 2023. 139 funds tracked by Wall St. Rank hold NRIX as of Q1 2024.

B. Metzler seel. Sohn & Co reported no remaining Nurix Therapeutics position as of Q1 2024 after selling out during the quarter.
B. Metzler seel. Sohn & Co sold 36,171 Nurix Therapeutics shares in Q1 2024, an estimated $373K.
B. Metzler seel. Sohn & Co first reported a position in Nurix Therapeutics in Q3 2022 and held it in 6 quarters.
B. Metzler seel. Sohn & Co's Nurix Therapeutics position peaked at $540K in Q2 2023.
139 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2024.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q1 2024, filed 15 May 2024.